Here are the 10-Q quarterly reports from PROCEPT BioRobotics Corporation (PRCT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PRCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRCT filings page.
PROCEPT BioRobotics Corp (PRCT) reported third-quarter revenue of $98.3 million, up 18% from a year earlier, and nine-month revenue of $275.9 million, up 19%. Handpieces and other consumables and service revenue increased; U.S. revenue was $85.8 million in the quarter. Gross margin was 66%, compared with 65%, and the company attributed the increase primarily to $3.2 million of tariff refunds.
Net loss was $26.5 million for the quarter versus $21.4 million, and $85.0 million for nine months versus $65.7 million. Nine-month operating cash use was $66.4 million, compared with $38.7 million. As of September 30, 2026, cash and cash equivalents were $218.4 million and term-loan principal outstanding was $52.0 million. The loan maturity was extended by 12 months to October 1, 2028; the company reported compliance with all debt covenants. Management currently believes existing cash and anticipated revenue will fund operations through at least 12 months from the financial statements’ issuance date. The company had 1,095 robotic systems installed globally, including 858 in the United States.
PROCEPT BioRobotics reported first-quarter 2026 revenue of $83.1 million, up 20% from $69.2 million a year earlier, driven by higher system sales, consumables, and service, mainly in the United States.
Gross margin improved slightly to 65%, but the company’s net loss widened to $31.6 million, reflecting increased research, sales, and administrative spending to support growth. Operating cash outflow was $38.1 million, and cash and cash equivalents totaled $245.6 million with $52.0 million of term debt outstanding. The global installed base reached 971 robotic systems, including 765 in the U.S.
PROCEPT BioRobotics (PRCT) reported strong Q3 growth with continued losses. Revenue reached $83.3 million, up 43% year over year, driven by higher system placements, handpieces, and service. Gross margin improved to 65% from 63% as higher volumes spread fixed manufacturing costs. Net loss was $21.4 million, or $0.38 per share, compared to $21.0 million, or $0.40 per share, a year ago.
For the first nine months, revenue was $231.7 million, up 48%, with gross margin at 65%. Cash and cash equivalents were $294.3 million as of September 30, 2025, and stockholders’ equity was $380.3 million. The company had $51.6 million of long‑term debt and amended its loan in August 2025 so the entire principal is due at maturity in 2027, alongside updated cash‑holding requirements tied to balance thresholds. U.S. accounted for 89% of Q3 revenue. The installed base reached 835 AquaBeam and HYDROS robotic systems globally, including 653 in the United States. Shares outstanding were 55,878,589 as of October 29, 2025.